Krishnan Mahesh

Halozyme Therapeutics, Inc. · Director

Krishnan Mahesh serves as a Director at Halozyme Therapeutics, Inc., a company known for its innovations in the healthcare sector. His trading activity is documented through SEC Form 4 filings, revealing a focus on sale transactions. Between May 2, 2025, and June 30, 2026, Mahesh reported six disclosures, all related to Halozyme Therapeutics (ticker: HALO), with the largest sale valued at $547.8K.

Latest Trades

CompanyValueActionPriceLast Price
Halozyme Therapeutics, Inc.HALO$548k7.3k sharesSellJun 29, 2026$75.00$77.54